Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01119664 · ClinicalTrials.gov registry record · Phase 1
Combination Gene Transfer and Chemotherapy
A Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01119664 is a Phase 1 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 40 participants.
The verdict
NCT01119664, a Phase 1 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to find the safety of combination gene therapy and chemotherapy in patients with malignant pleural mesothelioma. Pleural catheter will be placed first, then pts will receive 2 doses of intrapleural vector followed by front line or second line chemotherapy 4-6 cycles every 21 days.
Interventions
- DRUG SCH 721015
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2010-04-27 |
| Est. Completion | 2017-03-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01119664
The ClinicalTrials.gov registry entry for NCT01119664 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SCH 721015 is the first listed.
NCT01119664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01119664 about?
NCT01119664 is a clinical study titled "Combination Gene Transfer and Chemotherapy". The purpose of this study is to find the safety of combination gene therapy and chemotherapy in patients with malignant pleural mesothelioma. Pleural catheter will be placed first, then pts will receive 2 doses of intrapleural vector followed by front line or second line chemotherapy 4-6 cycles ever...
What is the current status of trial NCT01119664?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2010-04-27. Estimated completion is 2017-03-17.
What interventions are being tested in trial NCT01119664?
The interventions under investigation include: SCH 721015 (DRUG).
Who is sponsoring clinical trial NCT01119664?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.